Company profileNeuromodulation
ReEmerge
Deep brain stimulation of the central thalamus, to restore cognitive function years after a traumatic brain injury.
- Location
- United States
- Class
- NeuromodulationDeep brain stimulation that, as far as is public, stimulates without sensing: no neural signal is read out or decoded. It is part of the wider neural-interface landscape and is not counted as a BCI company.Not counted among core BCI companies.
- Also known as
- ReEmerge, Inc. · Cognitive Network Restoration Therapy · CNRT
- Website
- reemergeinc.com
- Funding stage
- Series A
- Sources last checked
- 5 Oct 2026
What they are building
Develops an implanted stimulation system it calls Cognitive Network Restoration Therapy. Electrodes in the central thalamus drive brain networks that survived the injury and are underactive. The approach comes from two decades of academic work at Weill Cornell and Stanford.
- Interface category
- Deep brain stimulation
- Signal
- Continuous electrical pulses
- Invasiveness
- Invasive
- Recording / stimulation
- Stimulation
- Main use cases
- Restore
- Works with
- Stanford University
Where they are clinically
First-in-human
The first use of a device in a small number of people, focused on safety.
The human evidence is an academic phase 1 study, led by the company's scientific founders and published in 2023, in which five participants completed treatment. ReEmerge's own feasibility study is registered and not yet recruiting; the registry gives February 2027 as its planned start. The company is reported to be based in Minnesota.
Access today
Experimental human research
Demonstrated in a small number of research participants. Not an established treatment.
- Shown in people
- Five participants completed an academic phase 1 study of central thalamic stimulation after traumatic brain injury (Nature Medicine, 2023).
- Still an aim
- A 40-participant feasibility study, registered and not yet recruiting, with a planned start in February 2027.
- What stands in the way
- Replication at scale. And it stimulates without sensing, which keeps it outside BCI for now.
On record here: 0 peer-reviewed papers
This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.
Why this company matters
ReEmerge is worth following from a BCI point of view for what it is not. It writes to the brain and does not read from it, so it sits beside the field rather than in it. But it targets a very large group of people with no device therapy at all, on a peer-reviewed human result, with electrodes in a deep structure that surface and intracortical interfaces do not reach. If stimulating the central thalamus holds up in a 40-participant study, the argument for sensing and adapting that stimulation, which is where neuromodulation and BCI meet, follows naturally.
Key milestones
15 Sep 2026
Emerges from stealth with a $37M Series A co-led by U.S. Venture Partners and Santé Ventures.
28 Jul 2026
The company's feasibility study is registered: 40 participants planned, not yet recruiting.
Dec 2023
Phase 1 feasibility study of central thalamic stimulation in moderate-to-severe traumatic brain injury is published in Nature Medicine; five participants completed treatment.
Funding history
- 15 Sep 2026$37MSeries A · led by U.S. Venture Partners, Santé VenturesDeep brain stimulation for traumatic brain injury: neuromodulation, not a BCI. Counted in the sample under its own class.
Investors namedU.S. Venture Partners · Santé Ventures · Oxford Science Enterprises · 415 Capital · IAG Capital Partners · The Vertical Group · Dendrion Ventures
Rounds in the Briefing’s sample only; not a complete funding history.
Leadership
Todd Langevin
Chief executive
Nicholas Schiff
Scientific co-founder
Jaimie Henderson
Scientific co-founder
As publicly stated by the organisation. Not a complete list.
Competitive context
ECoGFeasibility
Motif Neurotech
A miniature, wirelessly powered brain stimulator for treatment-resistant depression.
ECoGFeasibility
ONWARD Medical
Spinal cord stimulation therapies, with a brain–spine interface in development.
ECoGFirst-in-human
CorTec
A fully implanted closed-loop system that both records from and stimulates the cortical surface.
Sources
- 01
ReEmerge: company website (opens in a new tab)
Company reportedReEmerge, Inc.Checked against source 5 Oct 2026
Names the leadership and the scientific founders, describes the therapy as central thalamic deep brain stimulation and states that the device is investigational. Says nothing about sensing or closed-loop operation.
- 02
Independent reportingAllSci16 Sep 2026Checked against source 5 Oct 2026
Gives the amount, the co-leads and five further investors, the planned 40-participant study and the 2023 phase 1 result. Places the company in Minnesota without naming a city.
- 03
Peer reviewedNature MedicineDec 2023Checked against source 5 Oct 2026
DOI 10.1038/s41591-023-02638-4. Citation confirmed against the PubMed record; the number of participants who completed treatment (five) is taken from the abstract of the group's 2026 follow-up paper in Brain Communications.
- 04
Clinical registryClinicalTrials.govChecked against source 5 Oct 2026
Sponsor ReEmerge, Inc. Not yet recruiting; 40 participants planned; start given as February 2027. First posted 28 July 2026. No sites are listed.